2.4.0.84010 - Disclosure - Nature of the Business (Details)truefalseIn Millions, except Share data, unless otherwise specifiedfalse1false USDfalsefalseD2013Q2YTDhttp://www.sec.gov/CIK0001274792duration2013-01-01T00:00:002013-06-30T00:00:00ItemStandardhttp://www.merrimackpharma.com/20130630itemmack0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$2false USDtruefalse$D2013Q3_M0717_SubsequentEventMemberhttp://www.sec.gov/CIK0001274792duration2013-07-16T00:00:002013-07-17T00:00:00falsefalseSubsequent eventsus-gaap_SubsequentEventTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SubsequentEventMemberus-gaap_SubsequentEventTypeAxisexplicitMemberSharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDtruefalse$D2013Q3_M0717_ConvertibleDebtMember_SubsequentEventMemberhttp://www.sec.gov/CIK0001274792duration2013-07-16T00:00:002013-07-17T00:00:00falsefalseConvertible senior notesus-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ConvertibleDebtMemberus-gaap_DebtInstrumentAxisexplicitMemberfalsefalseSubsequent eventsus-gaap_SubsequentEventTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_SubsequentEventMemberus-gaap_SubsequentEventTypeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$1true 1us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Nature of the Business2false 2mack_NumberOfNovelTherapeuticOncologyCandidatesInClinicalDevelopmentmack_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse66falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of novel therapeutic oncology candidates in clinical development of the entity.No definition available.false256Number of novel therapeutic oncology candidates3false 2us-gaap_CashCashEquivalentsAndShortTermInvestmentsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse6210000062.1USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 8, 9, 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Unrestricted cash and cash equivalents and available-for-sale securities4true 3mack_SaleOfStockLineItemsmack_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Public Offering5false 4us-gaap_StockIssuedDuringPeriodSharesNewIssuesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsepositiveLabel1falsefalsefalse00falsefalsefalse2truefalsefalse57500005750000falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of new stock issued during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Shares of common stock sold in underwritten public offering6false 4us-gaap_DebtInstrumentInterestRateStatedPercentageus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3truetruefalse0.04500.0450falsefalsefalsenum:percentItemTypepureInterest rate stated in the contractual debt agreement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false0Interest rate (as a percent)7false 4us-gaap_DebtInstrumentIncreaseAdditionalBorrowingsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse125000000125.0falsefalsefalsexbrli:monetaryItemTypemonetaryIncrease of additional borrowings on existing and new debt instruments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(f)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph f -Article 4 false2Notes issued8false 4mack_ProceedsFromIssuancePublicEquityAndConvertibleSeniorNotesOfferingNetOfOfferingCostsmack_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse147400000147.4USD$falsetruefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from the entity's sale of common stock and convertible senior notes, net of offering costs.No definition available.false2Net proceeds from sale of common stock and convertible senior notesfalseNature of the Business (Details) (USD $)HundredThousandsNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://www.merrimackpharma.com/role/DisclosureNatureOfTheBusinessDetails38